100% U.S. Tariff on Patented Drug Imports Takes Effect for Major Drugmakers

A 100% Tariff Just Landed on the World's Biggest Drugmakers. Almost Nobody Will Pay It.

The number is 100%. Since July 31, 2026, that's the tariff rate on imported patented medicines from the world's largest drugmakers — Novo Nordisk, Pfizer, Eli Lilly, AbbVie, Novartis and others named in a presidential order^[1][6]. Smaller companies join them on September 29, 2026^[1][6].

But almost nothing is actually taxed at 100%. Drugs from the European Union, Japan, South Korea, Switzerland and Liechtenstein pay 15% instead^[1][9]. Companies that agree to build U.S. plants pay 20% through 2030^[1][5]. And more than a dozen major drugmakers — including Lilly, Pfizer and Novo Nordisk — have three-year exemptions tied to separate deals to cut U.S. prices^[7][17]. Generic drugs, which make up most U.S. prescriptions, pay nothing until 2028^[1][7].

That gap between the headline number and the real one is the whole story. It's not a loophole. It's the design.

Why a Security Law, Not an Emergency Order

The tariff comes from Proclamation 11020, signed April 2, 2026, under Section 232 of the Trade Expansion Act of 1962 — a law that lets a president restrict imports he finds threaten national security^[1][20]. That's a specific and unusual legal path, and the reason for it matters.

In February 2026, the Supreme Court ruled that a different law, the International Emergency Economic Powers Act, gives the president no tariff power at all^[13]. Chief Justice Roberts, writing for the majority, pointed to Section 232 as an example of tariff authority Congress actually did hand over^[13]. So this program runs through a formal Commerce Department investigation and a national-security finding, not an emergency declaration. It's slower to set up. It's also much harder to strike down in court^[13].

The security finding itself points to a real vulnerability. Officials cite data showing 83% of the top 100 generic drugs Americans take have no U.S.-made active ingredient, and the raw materials for amoxicillin come almost entirely from China^[16]. That's the case the administration leads with: not prices, but dependence.

The Deals Behind the Discounts

Here's the mechanism that determines what a company actually pays, and it's worth understanding because it's the crux of the whole dispute. The Commerce Department, starting May 13, 2026, opened a process for companies to apply for "onshoring agreements" — binding, company-specific commitments to move production to U.S. soil, in exchange for a lower 20% tariff rate through April 2030^[1][2][5].

This means the tariff a company pays isn't set by a public rulebook. It's negotiated, one company at a time, with the federal government. Drugmakers have announced more than $480 billion in planned U.S. manufacturing since 2025 — Roche and Novartis alone pledged a combined $73 billion, or 58 billion Swiss francs, to win Switzerland's 15% rate^[9][10][14]. The administration treats that total as proof the pressure is working^[14].

Critics on the free-market right see it differently. A Washington Examiner analysis calls the arrangement "state capitalism" — rates won through negotiation with the president rather than through a rule applied equally to everyone^[12]. That system rewards companies large enough to negotiate directly with the White House. Small biotechs mostly aren't in the room^[12].

The Argument Both Sides Actually Win

Strip away the politics and there's a genuine, unresolved technical dispute at the center of this: even if every company signs on, how fast can any of this actually happen? A new drug plant isn't a warehouse you can lease and open in a season. It takes years to build, and then the FDA has to inspect and validate it before a single approved pill can ship^[7].

India's generic-drug trade group puts the floor for building a domestic generic supply chain at four to five years, minimum^[7]. That's not a stalling tactic — it's closer to physics than politics. The tariff started collecting money in July 2026. Any new U.S. supply it's meant to encourage won't exist until well into the 2030s^[7].

That timing gap is why an industry consultant told CNBC that a 100–200% tariff on a product with single-digit profit margins amounts to "a market-exit notice"^[7]. His comment was about the separate, later tariff schedule for generic drugs, not this week's patented-drug tariff — but the underlying math is the same problem facing branded drugmakers now^[7]. Meanwhile, the administration argues the design already accounts for this: generics, biosimilars and drugs for rare diseases are excluded specifically because they're the products companies have the least room to absorb costs on^[1].

One Number, Read Two Different Ways

There's a second mechanism worth understanding, because it will likely decide how much money actually changes hands: transfer pricing. Much of the "imported" medicine in this story isn't one company selling to another. It's a drugmaker shipping product from its own overseas factory to its own U.S. sales arm^[7][8]. Customs charges the tariff on the value declared for that internal shipment — and companies have some legal latitude in how they set that internal price^[7][8].

That gives firms a way to shrink their tariff bill without necessarily changing what a pharmacy charges a patient. Analysts expect that lever to get used, and scrutinized^[7][8]. It also means the headline 100% rate may say very little about what a company's actual tax bill turns out to be, or what a patient eventually pays.

For exporting countries, the number carries a different weight entirely. In Switzerland, pharmaceuticals make up roughly 7% of the entire economy, about $35 billion in exports to the U.S. in 2024, and 50,000 jobs^[9][10]. Swiss coverage of the 15% rate consistently frames it as forced sacrifice — the price of avoiding a threatened rate as high as 39%, paid for with $73 billion in pledged U.S. investment and an estimated 3 billion Swiss francs in tax revenue now at risk if production actually moves^[9][10][19].

What Would Actually Settle This

Both sides agree on the underlying fact: tariffs raise the cost of bringing a drug into the U.S. What they disagree on is what happens to that cost next — whether a company absorbs it, raises prices on new drugs, adjusts its internal transfer prices, or simply pulls a low-margin product from the U.S. market^[7][8].

That's not a question anyone can answer from a podium. It's a question earnings reports start answering this week, since this is the first reporting period in which drugmakers have actually owed the tariff^[7]. The measurements that would settle the argument — tariff revenue actually collected, launch prices on new patented drugs, product withdrawal notices, FDA shortage listings — don't exist yet^[7][14][15].

Notably, almost nobody involved has a strong incentive to say plainly that the effect on patients is still, for now, mostly unmeasured. The administration wants credit for a security fix that's already working. Drugmakers want credit for the capital they've already committed. Exporting governments want the story told in terms of what they were forced to give up^{[7][9][10][14]}. The claim that prices will spike and the claim that patients are protected are, right now, both still forecasts.